Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model - PubMed (original) (raw)

doi: 10.1038/cgt.2008.98. Epub 2008 Dec 19.

Affiliations

PMID: 19096447
DOI: 10.1038/cgt.2008.98

Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model

S H Yoon et al. Cancer Gene Ther. 2009 Jun.

Abstract

The current gene transfer technology for single chain (scFv)-based chimeric immune receptor (CIR) has relied on retrovirus and lentivirus vectors which require a long time to obtain sufficient number of transduced cells and stably incorporate into genome. To ameliorate these limitations, we applied RNA electroporation to human peripheral blood lymphocytes (PBLs) activated with anti-CD3 antibody and interleukin-2 (IL-2) for 3 days and assessed that PBL transiently expressing anti-Her-2/neu CIR (CIR-PBL) containing signaling portion of CD28 and CD3zeta could elicit strong cytotoxicity in vitro and antitumor responses in vivo. The CIR-PBL expressed high level of CIR in CD4+, CD8+ and CD56+ cells. Her-2/neu-specific stimulation induced secretion of type-I cytokines including interferon-gamma (IFN-gamma), IL-8 and granulocyte-macrophage colony-stimulating factor, and IFN-gamma secretion was mainly mediated by CD8+ T cells. CIR-PBL specifically killed SKOV3 cell line expressing Her-2/neu. Adoptive transfer of CIR-PBL in SKOV3 xenograft model led to significant inhibition of tumor growth compared with transfer of mock-transduced PBL and showed higher inhibition than those with Herceptin, humanized monoclonal antibody specific for Her-2/neu. These results provided evidence that electroporation of CIR RNA to human PBLs could be used for rapid generation and high number of therapeutic antigen-specific T cells for adoptive immunotherapy.

PubMed Disclaimer

Cited by

Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.
Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, Albelda SM, June CH. Zhao Y, et al. Cancer Res. 2010 Nov 15;70(22):9053-61. doi: 10.1158/0008-5472.CAN-10-2880. Epub 2010 Oct 5. Cancer Res. 2010. PMID: 20926399 Free PMC article.
Emerging CAR T Cell Strategies for the Treatment of AML.
Vishwasrao P, Li G, Boucher JC, Smith DL, Hui SK. Vishwasrao P, et al. Cancers (Basel). 2022 Feb 27;14(5):1241. doi: 10.3390/cancers14051241. Cancers (Basel). 2022. PMID: 35267549 Free PMC article. Review.
From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy.
Firor AE, Jares A, Ma Y. Firor AE, et al. Exp Biol Med (Maywood). 2015 Aug;240(8):1087-98. doi: 10.1177/1535370215584936. Epub 2015 May 7. Exp Biol Med (Maywood). 2015. PMID: 25956686 Free PMC article. Review.
mRNA-based therapeutic strategies for cancer treatment.
Taibi T, Cheon S, Perna F, Vu LP. Taibi T, et al. Mol Ther. 2024 Sep 4;32(9):2819-2834. doi: 10.1016/j.ymthe.2024.04.035. Epub 2024 May 3. Mol Ther. 2024. PMID: 38702886 Review.
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.
Kalos M, June CH. Kalos M, et al. Immunity. 2013 Jul 25;39(1):49-60. doi: 10.1016/j.immuni.2013.07.002. Immunity. 2013. PMID: 23890063 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model - PubMed (original) (raw)